ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2015 - 2022)

ImmunityBio (IBRX) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $162000.0 in Q2 2022.

• Quarterly Non-Current Deferred Tax Liability fell 4.71% year-over-year to $162000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $162000.0 (down 4.71% YoY) and the FY2021 annual result came in at $162000.0, down 96.65% from the prior year.
• Non-Current Deferred Tax Liability held at $162000.0 in Q2 2022 per IBRX's latest filing, from $162000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $4.8 million in Q4 2020 and bottomed at $122000.0 in Q3 2018.
• The 4-year median for Non-Current Deferred Tax Liability is $170000.0 (2021), against an average of $658000.0.
• The widest annual swing landed in 2021, when Non-Current Deferred Tax Liability sank 96.65%; it then declined 4.71% in 2022.
• Tracing IBRX's Non-Current Deferred Tax Liability over 4 years: stood at $122000.0 in 2018, then soared by 3865.57% to $4.8 million in 2020, then slumped by 96.65% to $162000.0 in 2021, then changed by 0.0% to $162000.0 in 2022.
• Per Business Quant, the three latest IBRX Non-Current Deferred Tax Liability figures stand at $162000.0 (Q2 2022), $162000.0 (Q1 2022), and $162000.0 (Q4 2021).

Peer Comparison